Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Smith

Showing results (261-270 of 267) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 267 results.
Applied and Environmental Microbiology|March 10, 2004
Temporal shedding patterns and virulence factors of Escherichia coli serogroups O26, O103, O111, O145, and O157 in a cohort of beef calves and their damsM C Pearce, C Jenkins, L Vali, et al.
HIV Medicine|July 14, 2005
Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapyM R Boulassel, G H R Smith, M D de B Edwardes, et al.
BMC Geriatrics|December 23, 2025
A cohort study of growth differentiating factor - 15 (GDF-15) and Interleukin-6 (IL-6) as biomarkers of healthy aging in older adults living with HIVMiriam Dushoff, Dawn M E Bowdish, Alice Zhabokritsky, et al.
Communicable Disease and Public Health|February 5, 2003
Collaborative investigation of an outbreak of Salmonella enterica serotype Newport in England and Wales in 2001 associated with ready-to-eat salad vegetablesL R Ward, C Maguire, M D Hampton, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
AIDS (London, England)|November 11, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE TrialMarissa R Diggs, Sarah M Chu, Kathleen V Fitch, et al.
Pageof 27

Showing results (261-270 of 267) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 267 results.
Applied and Environmental Microbiology|March 10, 2004
Temporal shedding patterns and virulence factors of Escherichia coli serogroups O26, O103, O111, O145, and O157 in a cohort of beef calves and their damsM C Pearce, C Jenkins, L Vali, et al.
HIV Medicine|July 14, 2005
Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapyM R Boulassel, G H R Smith, M D de B Edwardes, et al.
BMC Geriatrics|December 23, 2025
A cohort study of growth differentiating factor - 15 (GDF-15) and Interleukin-6 (IL-6) as biomarkers of healthy aging in older adults living with HIVMiriam Dushoff, Dawn M E Bowdish, Alice Zhabokritsky, et al.
Communicable Disease and Public Health|February 5, 2003
Collaborative investigation of an outbreak of Salmonella enterica serotype Newport in England and Wales in 2001 associated with ready-to-eat salad vegetablesL R Ward, C Maguire, M D Hampton, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
AIDS (London, England)|November 11, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE TrialMarissa R Diggs, Sarah M Chu, Kathleen V Fitch, et al.
Pageof 27